Patent · US Active

Precision medicine by targeting PD-L1 variants for treatment of cancer

US9045545B1 · kind B1 · utility

33Cited by
59References
15Claims
0Family size

Assignee

Inventor

Key dates

Filing dateNov 7, 2014
Grant dateJun 2, 2015
Priority date
Expiry dateNov 7, 2034

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Q2600/156
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.